A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

And lawmaker talk of PBM reform has returned. Will action follow?

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

The U.K. Will Make Efforts to Boost Drug Prices in Return for the Elimination of U.S. Tariffs

And the pharm-to-table pricing of obesity medicines gets even more dizzying as Lilly cuts the price of Zepbound vials

The Search for Clarity on the Differences Between IRA and MFN Prices for Ozempic and Wegovy

And an FDA official calls out ‘unique financial incentives for vaccine makers’

Medicare Negotiated Prices Are Out for 15 More Drugs. Here’s What We Know

Today Is Mostly a Day for Waiting

Still, links to ponder on CMS hospital payments, the price of gene therapies, and UK price negotiations

The Universe of Direct-to-Business Obesity Options Continues to Expand

And more 340B stories than you can shake a stick at

The Pharm-to-Conference-Table Trend Is Picking Up Steam

And a CMS advisor offers a peek behind the curtain on the agency’s myriad drug-pricing workstreams

When Will CMS Publish the Next Set of ‘Negotiated’ Prices for Medicare?

And could states create a “Netflix” model to balance obesity-med spending and access?

Why a New Drug Just Entered the Market With a List Price One-Tenth of Its Rival

And a Health Affairs Forefront piece brings much-needed clarity to the 340B rebate model conversation

The Five Most Interesting Things Lilly’s Dave Ricks Said on the Cheeky Pint Pod

Drugmakers and the government argue 340B rebate models in federal appeals court

The Obesity Pricing Paradigm Gets Even More Complex With Novo’s $199 Wegovy Offer

And a ranked list of a dozen other stories from the past 96 hours

CMS Is About to Announce ‘Negotiated’ Prices on 15 More Medicines. Here’s What the Companies Involved Have Said About Those Prices

Coming Soon to a Pharmacy Near You: Big List Price Cuts on Blockbuster Drugs

And Lilly’s health benefits plan will work with an upstart PBM

The Government Offers Its Most Detailed Description Yet of How to Calculate a ‘Most Favored Nation' Price

And Lilly expands its pharm-to-table offering, pledging to make Trulicity and Emgality available directly to patients

Even More on Medicare and Obesity: Newspapers Are Editorializing, Execs Are Explaining

Plus: Mark Cuban is trolling CVS, and I’m here for it

Putting Lilly and Novo’s White House Obesity Agreements Under the Microscope

And a model for bringing MFN prices to Medicaid hints at how those prices might be calculated

Today’s the Day: Lilly and Novo Are Set for a White House Deal on Obesity

And Novo’s earnings report sheds light on the Medicare obesity market and the impact of IRA “negotiations”

Lilly and Novo Are Reportedly Near a Deal, Offering $149 GLP-1s in Return for Coverage in Medicare

And Pfizer suggests that its MFN deal will leave a mark: “We expect a dilutive impact to our 2026 financial outlook.”

The Calm Before the Storm: Links on 340B, International Prices, and Obesity While We Wait for MFN, IRA, and PBM News

The Announcement of Prices in Medicare Are Coming Soon, With Earnings Calls Offering a Glimpse into Negotiations

Is it time for a $10 million gene therapy?

Cigna Details the Costs of Moving Its PBM Away From Rebates, Freaking Out Wall Street

And Lilly’s earnings call details a fundamental fact of the market: drug prices generally go down over time

GSK Says Medicare Negotiations Are Complete and ‘In Line With Expectations’

And two companies push back on a 340B loophole that allows for-profit doctors access to 340B prices

Another Quarter, Another Record: United’s PBM Unit Records Nearly $40B in Revenue, Over $1.5B in Profit

Plus STAT goes deep on Bausch Health’s decision to leave Medicaid/340B and more commentary on the Cigna/Express Scripts rebate announcement